Belpointe Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Belpointe Asset Management’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25	Closed	-$5.39K	–	3495
2023 Q1	$5.39K	Hold	25	–	–	﹤0.01%	2988
2022 Q4	$5.5K	Buy	+25	New	+$4.58K	﹤0.01%	2898
2018 Q4	–	Sell	-15,998	Closed	-$2.75M	–	649
2018 Q3	$2.75M	Buy	15,998 +12,138	+314%	+$2.04M	0.44%	35
2018 Q2	$593K	Buy	3,860 +81	+2%	+$14.4K	0.17%	126
2018 Q1	$635K	Sell	3,779 -12,129	-76%	-$1.64M	0.19%	115
2017 Q4	$1.55M	Buy	15,908 +40	+0.3%	+$3.66K	0.34%	60
2017 Q3	$1.64M	Buy	+15,868	New	+$1.18M	0.38%	52

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Belpointe Asset Management's ONC Position: Q2 2023 in Review

Belpointe Asset Management sold out of BeOne Medicines Ltd (ONC) in Q2 2023, closing a stake of 25 shares — an estimated $5.39K sold.

Belpointe Asset Management first reported a position in ONC in Q3 2017 and held it in 7 quarters. The position peaked at $2.75M in Q3 2018. 208 funds tracked by Wall St. Rank hold ONC as of Q2 2023.

Belpointe Asset Management reported no remaining BeOne Medicines Ltd position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 25 BeOne Medicines Ltd shares in Q2 2023, an estimated $5.39K.
Belpointe Asset Management first reported a position in BeOne Medicines Ltd in Q3 2017 and held it in 7 quarters.
Belpointe Asset Management's BeOne Medicines Ltd position peaked at $2.75M in Q3 2018.
208 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.